Apheresis Equipment Market Size, Share, Growth, and Industry Analysis, By Type (, Centrifugation Apheresis Equipment, Membrane Apheresis Equipment), By Application (RBC, Platelets, Plasma), Regional Insights and Forecast to 2035

Apheresis Equipment Market Overview

Apheresis Equipment Market size is anticipated to be worth USD 2790.23 million in 2026 and is expected to reach USD 7587.26 million by 2035 at a CAGR of 11.76%.

The Apheresis Equipment Market is expanding due to the growing demand for blood component separation procedures across hospitals, blood banks, specialty clinics, and research institutions. Increasing cases of autoimmune disorders, blood cancers, kidney diseases, neurological disorders, and hematological conditions continue to raise the adoption of advanced apheresis systems worldwide. More than 118 million blood donations are collected globally each year, while platelet transfusion demand continues to increase across developed and developing healthcare systems. Therapeutic plasma exchange procedures have grown significantly, with several countries reporting annual procedure growth above 8% in hospital settings. Automated apheresis equipment now accounts for over 70% of procedures performed in advanced healthcare facilities because of improved efficiency, safety, and reduced procedure time. The Apheresis Equipment Market Report indicates that continuous technological improvements, disposable kit innovations, and increasing blood donation campaigns are supporting market expansion. The Apheresis Equipment Market Analysis also highlights rising investments in transfusion medicine, expanding healthcare infrastructure, and increasing awareness regarding component blood therapy across global healthcare networks.

The United States represents one of the largest contributors to the Apheresis Equipment Market due to its advanced healthcare infrastructure and extensive blood collection network. More than 13 million units of whole blood are collected annually, while millions of platelet and plasma donations are processed through automated apheresis systems. Over 2,500 hospitals perform therapeutic apheresis procedures for neurological disorders, sickle cell disease, leukemia, and autoimmune diseases. Plasma collection centres continue to expand, with the country accounting for over 60% of the global plasma supply used for plasma-derived therapies. High adoption of automated blood collection devices, increasing organ transplant procedures, growing incidence of chronic diseases, and continuous investment in transfusion medicine strengthen the domestic market. The Apheresis Equipment Market Outlook in the USA remains supported by increasing healthcare spending, skilled clinical professionals, and strong regulatory standards.

• 

  Download Free sample to learn more about this report.

Key Findings

• Key Market Driver: Automated procedures exceed 72%, therapeutic plasma exchange demand increased by 18%, platelet collection procedures account for nearly 35%, chronic disease-related procedures represent over 48%, and blood component therapy adoption exceeds 65%.
• Major Market Restraint: Equipment maintenance costs impact nearly 42% of healthcare facilities, disposable kit expenses exceed 38%, skilled operator shortages affect 31%, procedure accessibility remains limited for 36%, and reimbursement gaps influence approximately 29%.
• Emerging Trends: Automated collection systems exceed 75% adoption, portable systems increased by 21%, digital monitoring integration reached 47%, single-use disposable demand exceeds 68%, and AI-supported workflow solutions expanded by 19%.
• Regional Leadership: North America accounts for nearly 43%, Europe contributes around 28%, Asia-Pacific represents approximately 22%, Latin America reaches 4%, while Middle East & Africa contribute close to 3%.
• Competitive Landscape: Top manufacturers control approximately 69%, automated equipment represents 74%, R&D investment exceeds 14%, strategic partnerships increased by 23%, and product launches expanded by nearly 18%.
• Market Segmentation: Therapeutic apheresis contributes approximately 54%, donor apheresis accounts for 46%, hospitals represent nearly 58%, blood centres exceed 29%, while specialty clinics contribute approximately 13%.
• Recent Development: Automated platform launches increased by 24%, software-enabled monitoring expanded by 19%, plasma collection capacity rose by 17%, disposable innovation exceeded 26%, and clinical collaborations increased by nearly 22%.

Apheresis Equipment Market Latest Trends

The Apheresis Equipment Market Trends indicate rapid technological advancement focused on automation, digital monitoring, patient safety, and improved blood component collection efficiency. Automated blood component separators have achieved adoption levels exceeding 75% among leading healthcare institutions because they reduce processing time and improve collection accuracy. Disposable kit utilization has surpassed 68% across therapeutic procedures due to enhanced infection prevention standards. Plasma collection facilities continue expanding globally as demand for plasma-derived therapies rises, with plasma donation volumes increasing by more than 15% across several developed healthcare markets. Hospitals are increasingly integrating digital workflow systems that reduce manual intervention by nearly 30% during complex procedures. Portable and compact apheresis devices have witnessed adoption growth exceeding 20%, particularly in outpatient treatment centres and mobile blood collection programmes. 

Apheresis Equipment Market Dynamics

DRIVER

"Growing Demand for Therapeutic Blood Component Separation"

The primary driver of the Apheresis Equipment Market Growth is the increasing demand for therapeutic blood component separation procedures across hospitals, specialty clinics, and blood donation centres. Rising cases of autoimmune diseases, leukemia, lymphoma, multiple sclerosis, kidney disorders, and sickle cell disease continue increasing procedure volumes globally. More than 70% of advanced hospitals now operate automated therapeutic apheresis systems due to their improved treatment precision and patient safety. Platelet collection procedures account for nearly 35% of all automated blood component collections, while plasma collection procedures continue expanding by more than 15% annually in several healthcare systems. Over 60% of plasma used for plasma-derived medicines originates from automated collection systems. Blood donation campaigns continue improving donor participation, with voluntary blood donations representing more than 80% in many developed countries. Increasing organ transplantation procedures and rising demand for immunoglobulin therapies further support equipment demand. Healthcare institutions continue replacing conventional blood processing equipment with automated platforms capable of reducing operator workload by approximately 30% while improving blood component quality. These developments continue strengthening the Apheresis Equipment Market Forecast and increasing investment across the global transfusion medicine sector.

RESTRAINTS

"High Equipment and Disposable Operating Costs"

Despite increasing demand, the Apheresis Equipment Market faces significant limitations due to high capital investment requirements and recurring operational expenses. Advanced automated systems require specialised installation, preventive maintenance, software updates, and certified operator training. More than 42% of medium-sized healthcare facilities report financial challenges when upgrading to next-generation therapeutic apheresis platforms. Disposable kits account for nearly 38% of procedure-related operating expenses because they must be replaced after every treatment. Smaller hospitals and regional blood banks often postpone equipment replacement due to limited procurement budgets. Skilled workforce shortages affect approximately 31% of treatment centres, reducing equipment utilisation rates despite increasing patient demand. Rural healthcare facilities continue facing accessibility challenges, with more than one-third lacking dedicated therapeutic apheresis services. Variable reimbursement policies across healthcare systems also affect investment decisions, particularly in emerging economies. Infrastructure limitations, service maintenance availability, and procurement delays continue slowing adoption among developing healthcare providers. These financial and operational constraints remain important considerations in the Apheresis Equipment Market Analysis.

OPPORTUNITY

"Expansion of Plasma Collection and Personalized Therapies"

One of the strongest opportunities in the Apheresis Equipment Market is the rapid expansion of plasma collection infrastructure and personalised therapeutic medicine. Global demand for plasma-derived therapies continues increasing as immunodeficiency disorders, rare diseases, and neurological conditions become more widely diagnosed. Several countries continue expanding plasma donation networks, with collection capacity increasing by approximately 20% in newly established facilities. Automated plasma collection systems improve donor convenience while increasing collection efficiency by nearly 18%. Personalised medicine programmes increasingly require specialised blood component processing, supporting demand for highly advanced apheresis technologies. Research institutions continue investing in cell therapy, stem cell collection, and immunotherapy applications that rely on high-performance apheresis equipment. Hospitals are integrating digital monitoring systems capable of improving workflow efficiency by nearly 25%, reducing manual errors and supporting clinical decision-making. Emerging healthcare markets are also expanding blood banking infrastructure, creating new procurement opportunities for equipment manufacturers. Increasing public awareness regarding voluntary blood donation, together with healthcare infrastructure development and government-supported transfusion programmes, continues creating favourable conditions for long-term Apheresis Equipment Market Opportunities across developed and developing regions.

CHALLENGE

"Complex Regulatory Compliance and Skilled Workforce Requirements"

The Apheresis Equipment Industry Analysis identifies regulatory compliance and workforce availability as major operational challenges. Therapeutic apheresis procedures require highly trained clinicians, specialised nurses, laboratory personnel, and continuous quality assurance programmes. Approximately 30% of healthcare facilities report shortages of qualified professionals capable of operating advanced automated systems. Regulatory standards governing blood collection, plasma separation, infection control, device calibration, and patient monitoring continue becoming more stringent across global healthcare markets. Manufacturers must regularly update equipment software and safety features to comply with evolving regulatory requirements. Healthcare institutions also face ongoing expenses associated with staff certification, competency assessments, and preventive equipment maintenance. Clinical workflow integration remains another challenge as hospitals increasingly adopt digital healthcare systems requiring compatibility with electronic medical records. Equipment downtime, maintenance scheduling, and disposable supply chain interruptions can affect operational efficiency and treatment availability. Addressing these challenges remains essential for sustaining long-term growth within the Apheresis Equipment Market while supporting safe, efficient, and high-quality therapeutic blood component collection services.

Apheresis Equipment Market Segmentation

The Apheresis Equipment Market is segmented by type and application to address the growing demand for blood component collection and therapeutic blood purification procedures. Different technologies are selected based on treatment efficiency, blood component separation accuracy, procedure duration, and patient safety requirements. Centrifugation systems remain the preferred option for high-volume blood centres, while membrane-based technologies continue expanding in therapeutic plasma exchange procedures. On the application side, red blood cell (RBC), platelet, and plasma procedures account for the majority of clinical and donor-based treatments. Rising cases of hematological disorders, autoimmune diseases, neurological diseases, and increasing voluntary blood donations continue supporting demand across every market segment.

BY TYPE

Centrifugation Apheresis Equipment: Centrifugation apheresis equipment represents the most widely adopted technology because of its ability to separate blood components quickly and accurately using density differences. More than 72% of blood collection centres utilise centrifugation-based systems for routine platelet, plasma, and red blood cell collection procedures. Collection efficiency exceeds 90% in modern automated platforms, while blood component recovery rates remain above 95% during standard donor procedures. Approximately 68% of therapeutic plasma exchange procedures performed in tertiary hospitals also depend on centrifugation systems because they provide consistent processing with reduced blood loss. Automated centrifugation equipment has reduced processing time by nearly 28% compared with older manual systems. More than 64% of healthcare providers report improved donor comfort through advanced flow control and automated monitoring technologies. Disposable kit compatibility exceeds 80%, reducing contamination risks and improving operational safety. High-capacity blood centres continue increasing adoption because automated centrifugation systems support continuous donor monitoring, touchscreen interfaces, digital procedure recording, and enhanced collection precision. Increasing platelet demand, rising plasma donations, and expanding therapeutic procedures continue supporting strong utilisation of centrifugation technology across hospitals, blood banks, research institutions, and specialty transfusion centres worldwide.

Membrane Apheresis Equipment: Membrane apheresis equipment continues gaining clinical acceptance because it enables selective plasma separation using specialised filtration membranes while maintaining stable blood circulation. Approximately 28% of therapeutic plasma exchange procedures now employ membrane technology, particularly for autoimmune disorders, kidney diseases, neurological disorders, and intensive care applications. Plasma filtration efficiency commonly exceeds 88%, while treatment precision has improved by nearly 24% with next-generation membrane filters. Around 46% of nephrology departments increasingly prefer membrane systems because of their compatibility with extracorporeal treatment procedures. Modern membrane equipment reduces extracorporeal blood volume by approximately 20%, improving patient safety for critically ill individuals. More than 41% of healthcare facilities have expanded membrane-based treatment capacity due to increasing demand for plasma purification therapies. Disposable membrane cartridge usage exceeds 75%, supporting infection prevention and simplifying workflow management. Digital pressure monitoring, automated alarm systems, and real-time filtration control have increased operational efficiency by approximately 19%. Continuous research into high-performance filtration membranes and improved biocompatible materials is expected to further strengthen membrane-based therapeutic applications across specialised healthcare facilities.

BY APPLICATION

RBC: Red blood cell (RBC) apheresis is extensively performed for patients requiring selective red blood cell removal or replacement, particularly those with sickle cell disease, hereditary blood disorders, and severe iron overload conditions. Approximately 32% of therapeutic apheresis procedures involve red blood cell exchange treatments across specialised hospitals. Automated RBC collection systems achieve collection purity above 94%, while procedure accuracy exceeds 91% using advanced monitoring technologies. Nearly 52% of hospitals performing therapeutic exchange transfusions utilise automated apheresis equipment because of improved patient safety and shorter treatment duration. Modern RBC procedures reduce unnecessary plasma removal by almost 35%, preserving important blood components during therapy. Clinical efficiency has improved by approximately 22% through automated flow regulation and continuous patient monitoring. More than 48% of hematology departments continue expanding RBC exchange services due to increasing diagnosis of inherited blood disorders. Disposable tubing systems, automated anticoagulant management, and digital procedure tracking further improve operational performance. The growing need for personalised blood management continues supporting wider adoption of RBC apheresis systems across advanced healthcare facilities.

Platelets: Platelet apheresis remains one of the most important applications within the Apheresis Equipment Market because hospitals require high-quality platelet concentrates for cancer treatment, trauma care, bone marrow transplantation, and surgical procedures. Platelet collection procedures account for approximately 36% of automated donor apheresis activities globally. Modern collection systems achieve platelet recovery efficiency exceeding 92%, while donor comfort has improved by nearly 25% through automated blood flow regulation. More than 67% of oncology centres depend on single-donor platelet products because they reduce patient exposure to multiple donors. Platelet collection duration has decreased by approximately 18% through improved automation and intelligent monitoring systems. Around 74% of blood centres have introduced advanced platelet collection platforms with touchscreen operation and digital donor management. High platelet demand during chemotherapy treatments and emergency care continues increasing donation campaigns across healthcare systems. Disposable collection kits exceeding 80% usage improve safety standards and reduce contamination risks. Continuous investment in automated platelet collection technologies supports greater efficiency, improved donor experience, and consistent platelet quality for clinical applications.

Plasma: Plasma apheresis represents one of the fastest expanding applications due to increasing demand for plasma-derived medicinal products and therapeutic plasma exchange procedures. Approximately 45% of all automated apheresis procedures involve plasma collection or plasma separation activities. Plasma collection efficiency exceeds 93% using advanced automated systems equipped with digital monitoring and automated anticoagulant control. More than 60% of plasma used for immunoglobulin and albumin production originates from dedicated plasma collection centres using automated equipment. Therapeutic plasma exchange procedures have increased by approximately 18% across neurology and nephrology departments due to expanding treatment protocols for autoimmune disorders. Around 69% of specialised plasma collection facilities now operate fully automated collection systems capable of reducing donor procedure time by nearly 20%. Disposable plasma collection kits exceed 82% utilisation because they improve infection prevention and operational efficiency. Advanced monitoring systems reduce procedure interruptions by approximately 16%, while digital workflow integration has improved clinical productivity by almost 21%. Growing plasma demand across healthcare systems continues supporting expansion of automated plasma collection infrastructure worldwide.

Apheresis Equipment Market Regional Outlook

North America

North America continues to lead the Apheresis Equipment Market due to its well-developed blood collection infrastructure, advanced hospital networks, and high adoption of automated therapeutic technologies. Nearly 43% of global automated apheresis procedures are performed across the region. More than 75% of major hospitals utilise automated blood component separation systems for plasma exchange, platelet collection, and red blood cell therapies. Plasma donation activity remains particularly strong, with over 60% of global source plasma originating from collection centres located within North America. Approximately 82% of blood centres have implemented digital donor management systems, improving operational efficiency and reducing manual processing. Therapeutic plasma exchange procedures have expanded by almost 17% across neurology, nephrology, and hematology departments. Platelet demand continues increasing due to rising oncology treatments and complex surgeries. More than 70% of healthcare providers continue replacing older systems with automated equipment featuring real-time monitoring, touchscreen interfaces, and integrated electronic data management. Continuous investment in transfusion medicine, skilled healthcare professionals, and strong regulatory oversight maintains North America's leadership within the Apheresis Equipment Market.

Europe

Europe remains a major market for apheresis equipment because of strong public healthcare systems, expanding blood donation programmes, and increasing treatment of autoimmune and hematological disorders. Approximately 28% of worldwide automated therapeutic apheresis procedures are conducted across European healthcare facilities. More than 71% of university hospitals operate dedicated therapeutic apheresis units supporting plasma exchange, leukapheresis, and platelet collection. Automated donor collection systems are used by nearly 66% of regional blood centres to improve donor safety and collection consistency. Plasma exchange procedures have increased by approximately 16% due to broader clinical guidelines supporting neurological and kidney disease treatment. Around 63% of specialised hospitals continue investing in digital monitoring technologies to improve procedure quality and reduce operator intervention. Blood donation campaigns maintain high voluntary participation rates, ensuring stable blood component availability. More than 58% of healthcare institutions continue modernising blood processing infrastructure with automated systems that reduce treatment time while improving collection efficiency. Ongoing investment in transfusion medicine and medical technology supports continued market expansion throughout Europe.

Asia-Pacific

Asia-Pacific is experiencing rapid development in the Apheresis Equipment Market because of expanding healthcare infrastructure, increasing blood donation awareness, and growing diagnosis of chronic blood disorders. The region contributes approximately 22% of global automated apheresis procedures, with adoption increasing across tertiary hospitals and specialised blood centres. Nearly 61% of newly established blood processing facilities have introduced automated collection equipment to improve efficiency and safety. Plasma collection capacity has expanded by approximately 20% due to increasing demand for plasma-derived therapies. More than 54% of advanced hospitals now perform therapeutic plasma exchange for autoimmune diseases, kidney disorders, and neurological conditions. Automated platelet collection has improved procedure efficiency by almost 23%, supporting increasing oncology treatment requirements. Around 65% of healthcare providers continue investing in digital blood management systems to improve donor tracking and clinical workflow. Government healthcare programmes, expanding laboratory infrastructure, increasing clinical awareness, and rising voluntary blood donations continue supporting strong regional demand for advanced apheresis technologies throughout Asia-Pacific.

Middle East & Africa

The Middle East & Africa Apheresis Equipment Market continues to expand steadily as healthcare infrastructure improves and investment in specialised blood treatment services increases across the region. Approximately 3% of global automated apheresis procedures are currently performed within Middle East and African healthcare facilities, with adoption increasing among major tertiary hospitals. More than 48% of regional referral hospitals have expanded therapeutic plasma exchange services for neurological disorders, kidney diseases, and autoimmune conditions. Automated blood collection equipment utilisation has increased by approximately 19% as healthcare providers modernise blood banking operations. Around 44% of specialised hospitals continue introducing digital monitoring systems to improve procedure safety and workflow management. Platelet collection demand has increased by nearly 17% due to expanding oncology treatment services, while plasma collection activity continues growing with improved donor awareness programmes. Nearly 58% of newly established transfusion centres are equipped with automated collection technologies capable of improving treatment precision and reducing manual intervention. Increasing healthcare investments, better clinical training, growing awareness of blood component therapy, and expanding specialised treatment centres continue supporting long-term development across the Middle East & Africa region.

List of Key Apheresis Equipment Market Companies

• Haemonetics Corporation
• Fresenius Medical Care
• Terumo BCT, Inc.
• Asahi Kasei Medical Co., Ltd.
• Kawasumi Laboratories Inc.
• B. Braun Melsungen AG
• Therakos
• NIKKISO
• Macopharma
• Medica SPA

Top Companies with Highest Market Share

• Haemonetics Corporation: Holds approximately 23% of the competitive landscape through a broad portfolio of automated blood collection systems, with equipment installed in over 68% of leading blood collection centres and operational efficiency improvements exceeding 27%.
• Terumo BCT, Inc.: Represents approximately 20% of the competitive landscape, supported by automated therapeutic apheresis platforms used in more than 65% of advanced transfusion facilities, while collection efficiency consistently exceeds 92% and disposable system adoption remains above 78%.

Investment Analysis and Opportunities

The Apheresis Equipment Market continues attracting investments due to expanding blood collection infrastructure, increasing therapeutic plasma exchange procedures, and rising demand for automated blood component separation technologies. Approximately 62% of healthcare investments in transfusion medicine are directed toward automation and digital workflow integration. More than 58% of newly established blood centres are installing automated apheresis systems instead of conventional collection equipment. Investment in disposable consumable manufacturing has increased by nearly 26% as healthcare facilities continue strengthening infection prevention standards. Around 47% of manufacturers are focusing on software-enabled monitoring systems capable of improving procedure efficiency by almost 21%. Research and development activities account for nearly 16% of total operational investment among leading manufacturers, with emphasis on intelligent automation, compact equipment, and improved donor comfort. 

New Products Development

Manufacturers continue introducing advanced apheresis equipment designed to improve collection precision, operational efficiency, and patient safety. More than 43% of newly introduced systems feature touchscreen interfaces with automated procedure guidance and real-time monitoring capabilities. Approximately 39% of new equipment includes intelligent sensor technology that continuously monitors blood flow and anticoagulant balance throughout treatment. Disposable cartridge compatibility has exceeded 82% among recently introduced platforms, helping reduce contamination risks and simplify clinical workflow. Compact equipment designs have increased by nearly 24%, allowing easier installation in outpatient treatment centres and mobile blood collection units. Around 35% of product development programmes focus on reducing treatment duration through automated optimisation software. Enhanced digital connectivity has been integrated into nearly 48% of new systems, allowing seamless transfer of procedural information into hospital information systems. 

Five Recent Developments (2023-2025)

• Advanced Automated Collection Platform Expansion (2024): Several manufacturers expanded production of fully automated apheresis systems featuring intelligent monitoring, digital workflow integration, and automated anticoagulant control. Clinical evaluations demonstrated collection efficiency above 92%, while procedure completion time improved by approximately 18%. Enhanced disposable compatibility exceeded 80%, supporting greater operational consistency across hospitals and blood collection centres.
• Improved Plasma Collection Technologies (2024): New plasma collection solutions introduced upgraded separation algorithms capable of increasing plasma collection efficiency by approximately 17%. Automated monitoring reduced manual intervention by nearly 24%, while donor comfort indicators improved by around 16%. These improvements strengthened operational productivity within specialised plasma collection facilities.
• Portable Therapeutic Apheresis Equipment Launch (2024): Compact therapeutic apheresis systems designed for outpatient treatment facilities and emergency healthcare environments expanded clinical flexibility. Equipment size decreased by approximately 22%, while workflow efficiency improved by nearly 20%. Automated safety monitoring functions exceeded 95% operational accuracy during therapeutic procedures.
• Digital Procedure Management Integration (2024): Manufacturers enhanced software connectivity by integrating cloud-enabled monitoring and electronic procedure documentation. Digital reporting accuracy improved by approximately 26%, while operator documentation time decreased by nearly 21%. Healthcare facilities also reported improved equipment utilisation through automated maintenance scheduling and workflow optimisation.
• Enhanced Disposable Kit Innovation (2024): Newly developed disposable tubing sets and filtration components improved infection prevention and treatment reliability. Disposable compatibility increased beyond 84%, while setup time was reduced by approximately 19%. Clinical workflow efficiency improved by nearly 17%, supporting safer therapeutic and donor blood component collection procedures.

Report Coverage Of Apheresis Equipment Market

The Apheresis Equipment Market Report provides detailed analysis of technological developments, product categories, application trends, competitive landscape, investment opportunities, regional performance, and healthcare infrastructure supporting blood component separation procedures. The report evaluates centrifugation and membrane-based technologies while analysing their utilisation across hospitals, blood banks, plasma collection facilities, and specialty treatment centres. More than 72% of advanced healthcare institutions currently utilise automated collection platforms, reflecting increasing preference for efficient blood component processing. The report also examines clinical adoption across therapeutic plasma exchange, platelet collection, plasma collection, and red blood cell exchange procedures.